Insights

Ablynx regains nanobody rights from Pfizer

BRUSSELS (Reuters) - Belgian biotech firm Ablynx said on Friday that it had regained the rights for its TNF-Alpha targeting nanobodies from Pfizer, which form the basis of a rheumatoid arthritis drug currently undergoing clinical trials. Pfizer said it…